2 Ioakeimidis 2018.

Study characteristics
Methods	Country: Greece Recruitment: Unclear, had previously been hospitalized with acute coronary syndrome Setting: Follow‐up conducted over the telephone and in clinics Study start date/Study end date: Not specified
Participants	Total N: 54 smokers ≥ 18 years old, smoking ≥ 10 cpd ib average in the past year and were hospitalized with acute coronary syndrome N per arm: varenicline = 27; electronic Cigarettes = 27 64.8% female, av age 52, av baseline weight 71.8, av cpd 21, av FTND 5.6
Interventions	12‐wk use of varenicline 12‐wk use of electronic cigarettes (EC; 12 mg/ml nicotine) All participants received low‐intensity counselling
Outcomes	1. Mean (SD) weight change (kg) in abstainers at EOT
Study funding	Not specified
Author declarations	Not specified
Notes	Information extracted from a conference poster and abstract Authors provided weight change data upon request for EOT; weight not measured at 26 week follow‐up This study is new to the 2021 update
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Similar amount of low‐intensity counselling between arms. Unable to blind participants due to nature of trial (varenicline vs EC)
Blinding of outcome assessment (detection bias) Smoking	High risk	Point prevalence smoking abstinence was defined by self‐report of complete abstinence in the 7 days before the 24‐week clinic visit
Blinding of outcome assessment (detection bias) Weight	Unclear risk	No information provided
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information provided